Answers are grounded in this paper and cite their sources.
Systematic review reveals early safety signals and translational challenges of CAR-NK therapy in colorectal cancer, suggesting a need for dedicated trials.
79 Background: Colorectal cancer (CRC) demonstrates limited responsiveness to current immune checkpoint inhibitors and breakthrough in chimeric antigen receptor–T cell (CAR-T) strategies face barriers in solid tumors. CAR–natural killer (CAR-NK) therapy offers potential advantages in safety and allogeneic scalability, yet the development of CRC-directed CAR-NK therapies remains unclear. We conducted a systematic review to define clinical signals and characterize translational engineering strategies of CAR-NK in CRC. Methods: A systematic search of PubMed, Scopus, ScienceDirect, Cochrane, and Wiley Online Library was conducted from inception through February 2026 (PROSPERO CRD420261324246). We included clinical studies administering CAR-NK therapy to patients with CRC, preclinical investigations evaluating CAR-NK platforms in CRC models, and registry-based trials permitting CRC enrollment were analyzed separately. Risk of bias was assessed using ROBINS-I and the SYRCLE risk of bias tool. Results: The available evidence was limited and early-stage, with only a small number of CRC clinical studies (<15 patients) complemented by a larger body of preclinical investigations and pan–solid tumor trials permitting CRC enrollment. Clinically, CAR-NK administration, including intraperitoneal mRNA-electroporated NKG2D CAR-NK and allogeneic NKG2D CAR-NK expressing membrane-bound IL-15 ± PD-1 blockade, was feasible and well tolerated, with no reported grade ≥3 cytokine release syndrome or neurotoxicity. Locoregional tumor control and immune activation were observed. However, durable systemic responses were infrequent. Combination therapy demonstrated enhanced immune activation compared with CAR-NK monotherapy. Registry analysis identified only one CRC-dedicated CAR-NK trial. Most active studies enroll CRC within basket designs rather than disease-specific cohorts. The termination of a MICA/B-directed CAR-NK program further highlights the limited and evolving clinical development landscape in CRC. Preclinical models demonstrated consistent antigen-dependent cytotoxicity across multiple CRC targets. Convergent engineering strategies addressed trafficking, microenvironmental resistance, antigen density, and persistence, with combination approaches outperforming monotherapy in xenografts. Conclusions: CRC-specific CAR-NK evidence remains promising, with signals of safety and localized activity but limited systemic efficacy. In contrast, preclinical innovation demonstrates strategic convergence toward multi-layer engineering and rational combination design. Dedicated CRC-focused trials are urgently needed to translate these advances into clinically meaningful outcomes.
No takes yet. Share an insight, caveat, or question.
Putra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: